This site is intended for health professionals only

Published on 21 June 2012

Share this story:
Twitter
LinkedIn

RyMed debuts advanced infection control system in EU

teaser

An improved system for helping to reduce the incidence of  deadly blood stream infections will make its European debut at the second World Congress on Vascular Access meeting being held in Amsterdam on 27–29 June 2012. 

Intravenous catheter care experts RyMed Technologies, Inc. are previewing their latest closed-system technology – the InVision-Plus CS® with Chlorhexidine+Silver Ion Engineering. Availability is expected in the second half of 2012.

This advanced, needleless system incorporates a chlorhexidine + silver ion impregnated septum as added protection against bacterial infection.  

RyMed’s education director, Paul Blackburn RN, BSN, MNA, VA-BC, the incoming President of the Association for Vascular Access, has been invited to share his expertise with delegates on the dangers of catheter related blood stream infections (CRBSI) and their impact on patients and hospital budgets.  His presentation ‘CVC vs PICC in the Intensive Care Unit’ will be held at 3 pm on Wednesday, 27 June 2012.

“These infections can be lethal – and also costly,” explains Mr Blackburn. “We have a duty of care to both patients and staff to provide enhanced infection control.”

The unique design of the InVision-Plus® with Neutral Advantage™ technology may reduce the incidence of bloodstream infections. It includes a patented double microbial barrier, zero fluid displacement and a straight-through fluid pathway with no dead space that makes it easier to completely flush blood from a catheter. 

Overall benefits include:
•    Improved bacterial control with chlorhexidine +silver ion impregnated septum  
•    More effective at killing pathogens than other silver-only, needleless connectors  
•    Long-lasting disinfection kills microbes for up to seven days 
•    Cost-effective and easy to use with standard 70% alcohol swabs

Hospital nurses and pharmacists are invited to learn more about the benefits by meeting the RyMed team at Booth D2.

Enquiries:

Call Carver Wilde Communications on +44 (0)20 3178 5563, or contact info@rymedtech.com

Resources: 
Video:
IV Connector Virtual Tour
CRBSI bundle (recommended evidence-based practices and devices to prevent CRBSI)
* Scientific poster comparing effectiveness of different 
IV connector types
* Summary of Infection Control Today article by William Jarvis, M.D. on different types of 
needleless connectors

About RyMed Technologies

Founded in 1994, RyMed Technologies, Inc., based in Tennessee, USA, specializes in the development and marketing of innovative safety products in the field of intravenous catheter care management. The company’s products are designed to help reduce catheter occlusions, catheter-related infections, and biofilm development commonly associated with vascular access devices. More than 10 years of research and development have gone into the InVision-Plus product line. Numerous studies regarding the efficacy of the InVision-Plus Needleless IV Connector have been published in the last six years-which is particularly important in light of the growing incidence of central line associated bloodstream infections (CLABSI).

More information on the product and published studies are available on www.rymedtech.com

iClinical Comparisons of Split Septum, Positive and Negative Mechanical Valve Needleless Connectors to an Intraluminal Protection Connector  On Infection Rates.  Macklin et al; A poster presented at APIC 2011.
iiAchieving Zero Catheter Related Blood Stream Infections:  15 Months Success in a Community Based Medical Center.  Harnage, JAVA Vol 12, No. 4, 2007.
iiiInvitro Study Assessing the Antibacterial Activity of Three Silver-Impregnated /Coated Mechanical Valve Needleless Connectors After Blood Exposure. Chernecky.  AJIC 2012
ivInvitro Study Assessing the Antibacterial Activity of Three Silver-Impregnated /Coated Mechanical Valve Needleless Connectors After Blood Exposure. Chernecky.  AJIC 2012
vInvitro study, Bactrin International, Belgrade, MT.  Report REC-00410, June 2010



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn